Sign in / Sign up
show more tags
Mergers And Acquisitions
Germany’s Fresenius in talks to buy generic drugmaker Akorn
Akorn Confirms Discussions with Fresenius, but no final decisions have been made.
Akebia, Vifor Pharma enter exclusive license pact over Vadadustat
Akebia Secures Exclusive Access to U.S. Dialysis Patients. Deal Includes $50M Equity Investment.
Fresenius Buys Akorn for $4.3 Billion
Acquisition of Akorn to strengthen and diversify core business and product portfolio.
Fresenius also made smaller purchase of biosimilar business.
FMC to buy U.S. home dialysis firm NxStage for $2 billion
Fresenius said it agreed to buy all shares of NxStage for $30 each, a 30% premium to their price on Friday of $23.14.
Dec 31, 1969
HANSESTARTUPS: Von Schiffsschrauben zum Startup-Campus